J Cell Biochem:脂肪酸合酶减少促进缺氧HepG2细胞死亡

2012-07-16 Beyond 生物谷

细胞在低氧胁迫情况下会激活一种适应性反应,而一旦细胞不采取适应性的反应就会发生细胞死亡现象。虽然有些机制已经被大量报道,单缺氧环境下细胞死亡的背后确切机制尚不清楚。 最近研究人员观察到在多种人类癌症中,脂肪酸合酶(FASN)的表达是增加的。在高增殖效率的细胞中,肿瘤相关的FASN被认为对膜脂的产生和蛋白的翻译后修饰是必要的,但确切的机制尚不完全清楚。 此外,FASN过度表达与恶性肿瘤的侵袭性有

细胞在低氧胁迫情况下会激活一种适应性反应,而一旦细胞不采取适应性的反应就会发生细胞死亡现象。虽然有些机制已经被大量报道,单缺氧环境下细胞死亡的背后确切机制尚不清楚。

最近研究人员观察到在多种人类癌症中,脂肪酸合酶(FASN)的表达是增加的。在高增殖效率的细胞中,肿瘤相关的FASN被认为对膜脂的产生和蛋白的翻译后修饰是必要的,但确切的机制尚不完全清楚。

此外,FASN过度表达与恶性肿瘤的侵袭性有关,并且抑制FASN作用能诱导癌细胞凋亡。出于这个原因,FASN正在成为一个潜在的诊断和治疗多种癌症的主要靶标。

在发表于J Cell Biochem杂志上的一项新研究中,科学家观察到在缺氧条件下,HepG2细胞FASN的表达是降低的。紧接着,研究人员分析了FASN表达下降对缺氧诱导的HepG2死亡的具体有何作用,还考察了FASN的表达减少对缺氧细胞死亡的具体作用机制。结果发现FASN表达的减少会导致丙二酰辅酶A的积累,进而导致细胞死亡。

doi:10.1002/jcb.24247
PMC:
PMID:

Reduced expression of FASN through SREBP-1 down-regulation is responsible for hypoxic cell death in HepG2 cells.

Jung SY, Jeon HK, Choi JS, Kim YJ.

Reduced expression of FASN through SREBP-1 down-regulation is responsible for hypoxic cell death in HepG2 cells.

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868558, encodeId=aa7a18685584b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 09 02:07:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958790, encodeId=2fa01958e9032, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 03 10:07:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916911, encodeId=c914191691166, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Aug 01 21:07:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2013-04-09 zhaozhouchifen

    #Cell#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1868558, encodeId=aa7a18685584b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 09 02:07:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958790, encodeId=2fa01958e9032, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 03 10:07:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916911, encodeId=c914191691166, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Aug 01 21:07:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2013-04-03 维他命

    #CEL#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1868558, encodeId=aa7a18685584b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 09 02:07:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958790, encodeId=2fa01958e9032, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 03 10:07:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916911, encodeId=c914191691166, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Aug 01 21:07:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2012-08-01 sunylz

    #Bio#

    0